Corvus Pharmaceuticals Inc Stock
Corvus Pharmaceuticals Inc took a tumble today and lost -€0.220 (-3.430%).
Corvus Pharmaceuticals Inc is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
With a target price of 10 € there is a hugely positive potential of 61.55% for Corvus Pharmaceuticals Inc compared to the current price of 6.19 €.
Our community identified positive and negative aspects for Corvus Pharmaceuticals Inc stock for the coming years. 0 users see the criterium "Brand" as a plus for the Corvus Pharmaceuticals Inc stock. On the other hand our users think that "Brand" could be a problem in the future.
Pros and Cons of Corvus Pharmaceuticals Inc in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corvus Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals Inc | -3.430% | -1.233% | -16.861% | 31.893% | 31.893% | 794.003% | 112.252% |
| Ardelyx Inc. | -1.080% | -0.244% | -3.002% | -1.067% | -1.067% | 106.821% | -14.929% |
| Krystal Biotech | 0.970% | 0.790% | 14.648% | 42.444% | 42.444% | 189.067% | - |
| Evolus Inc | -4.390% | -3.390% | -4.202% | -45.714% | -45.714% | -16.788% | 115.176% |
Comments
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target lowered by analysts at Mizuho from $12.00 to $11.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $17.00 price target on the stock, up previously from $15.00.
Show more
Ratings data for CRVS provided by MarketBeat
News
Corvus (CRVS) Q2 Loss Beats Estimates
Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies, released its earnings results for Q2 2025 on August 7, 2025
